Company Filing History:
Years Active: 2013-2015
Title: Mie Nieda: Innovator in Immunotherapy
Introduction
Mie Nieda is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of immunotherapy, particularly in the development of methods for the induction and activation of immune cells. With a total of 3 patents, his work is paving the way for advancements in disease treatment.
Latest Patents
Nieda's latest patents include a method for the simultaneous induction of CTL and γδ T cells. This innovative method allows for the culture of disease antigen-specific CTLs and γδ T cells in a single, efficient step. The process involves collecting blood, separating peripheral blood mononuclear cells, and adding aminobisphosphonate along with a disease antigen to promote the proliferation of these immune cells. The CTLs and γδ T cells produced are intended for therapeutic use in treating diseases.
Another notable patent is focused on the activation treatment of antigen-presenting cells. This method enhances the ability of antigen-presenting cells to induce disease antigen-specific CD8+ CTLs and/or γδ T cells both in vivo and in vitro. By co-pulsing these cells with bisphosphonate alongside a disease antigen, the effectiveness and quantity of the induced CTLs and γδ T cells are significantly increased.
Career Highlights
Mie Nieda is currently associated with Medinet Co., Ltd., where he continues to innovate in the field of immunotherapy. His work is characterized by a commitment to improving treatment methods for various diseases through advanced immunological techniques.
Collaborations
Nieda collaborates with talented individuals such as Manami Isogai and Mai Tomiyama, who contribute to his research and development efforts. Their teamwork enhances the potential for breakthroughs in immunotherapy.
Conclusion
Mie Nieda's contributions to immunotherapy through his patents and collaborative efforts are noteworthy. His innovative methods for inducing and activating immune cells hold promise for future advancements in disease treatment.